The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Pancreatic cancer survival edges up—as screening strategies emerge

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The American Cancer Society’s Cancer Facts & Figures 2023, released last week, reports that the five-year survival rate for pancreatic cancer is now 12%, an increase of one percentage point from last year.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Rosario Ligresti, MD
Chief, Division of Gastroenterology, John Theurer Cancer Center, Hackensack University Medical Center
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Nivolumab + epigenetic drug induce immune response in some resistant pancreatic cancers

In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 
Byline
Rosario Ligresti, MD
Chief, Division of Gastroenterology, John Theurer Cancer Center, Hackensack University Medical Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account